期刊文献+

白细胞介素2基因工程人大肠癌细胞瘤苗的建立及鉴定

Establishment of the interleukin-2 gene transferred human colorectal cancer cell vaccine
原文传递
导出
摘要 目的 建立高表达白细胞介素2的基因工程人大肠癌细胞瘤苗,并完成相关的实验室鉴定。方法 采用重组逆转录病毒将人白细胞介素2基因转导至三株人大肠癌细胞,G418筛选并挑选单克隆,ELISA检测各单克隆24h白细胞介素2表达量,用Student Newman Keuls检验三株细胞白细胞介素2的表达差异,PCR、Southern blot检测白细胞介素2基因整合,RT-PCR、Northern blot检测白细胞介素2基因转录水平。结果 获得72株G418抗性单克隆,其中表达量最高者为COL0205达138.01ng/L×10^7/24h,统计显示COLO205与SW1116、HT-29组间相比差异有统计学意义(P〈0.05),白细胞介素2基因整合至细胞基因组中,未发生重组或部分缺失,且获得成功表达。结论 本研究成功建立了高表达白细胞介素2的基因工程人大肠癌细胞瘤苗。 Objective To establish an interleukin-2 gene transferred human eoloreetal cancer cell vaccine. Methods Interleukin-2 gene was transferred into three human eoloreetal cancer cell lines with reeombined retrovirus. After using G418 to select monoelones, the secretion of interleukin-2 was determined by ELISA. Student Newman Keuls was used to examine the difference of three kinds of eoloreetal cancer cells; PCR,Southem blot to confirm the combination of interleukin-2 gene; RT-PCR,Northem blot to cheek the expression of interleukin-2 gene in mRNA level. Results We obtained 72 monoelones which may contain the objective gene. The highest secretion level was COLO205 of 138.01 ng/L × 10^7/24 hr. There was a significant difference between the production of IL-2 between COLO205 and SW1116, HT-29. We came to the conclusion that interleukin-2 gene was successfully combined to cell genome without recombination and exealation, and was translated correctly. Conclusions we succeeded in establishing the interleukin-2 gene transferred human eoloreetal cancer cell vaccine.
出处 《中华普通外科杂志》 CSCD 北大核心 2007年第9期698-701,共4页 Chinese Journal of General Surgery
基金 上海市自然科学基金(03ZR14048)
关键词 大肠癌 白细胞介素2 细胞瘤苗 基因转导 Coloreetal cancer Interleukin-2 Cell vaccine Gene transduetion
  • 相关文献

参考文献13

  • 1Eklund JW, Kuzel TM. Interleukin-2 in the treatment of renal cell carcinoma and malignant melanoma. Cancer Treatment and Research, 2005,126:263-287.
  • 2West WH, Tauer KW, Yannelli JR, et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med, 1987,316:898-905.
  • 3Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. JNCI,1993,85:622- 632.
  • 4Fabbri M, Ridolfi R, Mahoni R, et al. Tumor infiltrating lymphocytes and continuous infusion interleukin-2 after metastasectomy in 61 patients with melanoma, colorectal and renal carcinoma. Tumori, 2000,86:46-52.
  • 5Okuno K, Shigeoka H, Lee YS, et al. Adjuvant hepatic arterial IL-2 and MMC, 5-FU after curative resection of colorectal liver metastases. Hepatogastroenterology, 1996,43:688-691.
  • 6Schwartzentruber DJ. Interleukin-2 : clinical applications. Principles of administration and management of side effects. In: Rosenberg SA, ed. Principles and Practice of the Biologic Therapy of Cancer, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2000, pp 32-50.
  • 7Lee J, Moran JP, Koch CJ, et al. Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment. Cancer Res. 1998,58:1478-1485.
  • 8Lee J, Moran JP, Fenton BM, et al. Alteration of tumour response to radiation by interlcukin-2 gent transfer. Br J Cancer, 2000,82:937-944.
  • 9Li D, Ronson B, Guo M, et al. Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer. Cancer Res,2002,62:4023-4028.
  • 10Bash JA. Recombinant vaccinia interleukin-2-infected tumor cell vaccines in immunotherapy of murine colon adenocarcinoma. J Immunother, 1993,14:269-272.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部